A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Participants With Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) [IMpower 131]

Clinical Trial ID NCT02367794

Rank	Title	Journal	Year	PubWeight™‹?›
1	Checkpoint inhibitors in lung cancer: latest developments and clinical potential.	Ther Adv Med Oncol	2016	0.96
2	Advances in immunotherapy for treatment of lung cancer.	Cancer Biol Med	2015	0.95
3	Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors.	Invest New Drugs	2016	0.80
4	Recent Advances in Immunotherapy in Metastatic NSCLC.	Front Oncol	2016	0.79
5	Chemotherapy remains an essential element of personalized care for persons with lung cancers.	Ann Oncol	2016	0.77
6	Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting.	Ann Transl Med	2016	0.77
7	Immunotherapy for non-small cell lung cancer: current concepts and clinical trials.	Eur J Cardiothorac Surg	2015	0.77
8	Lung cancer in 2015: Bypassing checkpoints, overcoming resistance, and honing in on new targets.	Nat Rev Clin Oncol	2015	0.76
9	Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment.	Onco Targets Ther	2016	0.75
10	Pembrolizumab as first-line treatment for non-small cell lung cancer-a game changer?	Transl Lung Cancer Res	2016	0.75